Plasma biosignature and brain pathology related to persistent cognitive impairment in late-life depression

Molecular Psychiatry

Volumn 20, Issue 5, 2015, Pages 594-601

  Diniz, B S ^a   Sibille, E ^b   Ding, Y ^c   Tseng, G ^c   Aizenstein, H J ^b   Lotrich, F ^b   Becker, J T ^b   Lopez, O L ^b   Lotze, M T ^d   Klunk, W E ^b   Reynolds, C F ^b   Butters, M A ^b  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN A1; INTERLEUKIN 12; STEM CELL FACTOR; BENZOTHIAZOLE DERIVATIVE; BIOLOGICAL MARKER; N-METHYL-2-(4'-METHYLAMINOPHENYL)-6-HYDROXYBENZOTHIAZOLE; PROTEIN;

AGED; ARTICLE; CELL SURVIVAL; CEREBROVASCULAR DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GRAY MATTER; HUMAN; INFLAMMATION; INTRACELLULAR SIGNALING; LATE LIFE DEPRESSION; LIPID HOMEOSTASIS; MACHINE LEARNING; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEOMICS; SENSITIVITY AND SPECIFICITY; WHITE MATTER; BLOOD; BRAIN; COGNITION DISORDERS; COMPLICATION; DEPRESSION; DIAGNOSTIC IMAGING; IMAGE PROCESSING; METABOLISM; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; PSYCHOLOGICAL RATING SCALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BENZOTHIAZOLES; BIOMARKERS; BRAIN; COGNITION DISORDERS; DEPRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MACHINE LEARNING; MAGNETIC RESONANCE IMAGING; MALE; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; PROTEINS; PROTEOMICS; PSYCHIATRIC STATUS RATING SCALES;

EID: 84929129567     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2014.76     Document Type: Article

References (55)

1. Byers AL, Yaffe K, Covinsky KE, Friedman MB, Bruce ML. High occurrence of mood and anxiety disorders among older adults: The National Comorbidity Survey Replication. Arch Gen Psychiatry 2010; 67: 489-496
2. Viana MC, Andrade LH. Lifetime prevalence, age and gender distribution and ageof-onset of psychiatric disorders in the Sâo Paulo Metropolitan Area, Brazil: results from the Sâo Paulo Megacity Mental Health Survey. Rev Bras Psiquiatr. 2012; 34: 249-260
3. Butters MA, Whyte EM, Nebes RD, Begley AE, Dew MA, Mulsant BH, et al. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry. 2004; 61: 587-595
4. Bhalla RK, Butters MA, Becker JT, Houck PR, Snitz BE, Lopez OL, et al. Patterns of mild cognitive impairment after treatment of depression in the elderly. Am J Geriatr Psychiatry 2009; 17: 308-316
5. Reynolds CF 3rd, Butters MA, Lopez O, Pollock BG, Dew MA, Mulsant BH, et al. Maintenance treatment of depression in old age: a randomized, double-blind, placebo-controlled evaluation of the efficacy and safety of donepezil combined with antidepressant pharmacotherapy. Arch Gen Psychiatry. 2011; 68: 51-60
6. Köhler S, Thomas AJ, Barnett NA, OBrien JT. The pattern and course of cognitive impairment in late-life depression. Psychol Med 2010; 40: 591-602
7. Diniz BS, Butters MA, Albert SM, Dew MA, Reynolds CF 3rd. Late-life depression and risk of vascular dementia and Alzheimers disease: systematic review and metaanalysis of community-based cohort studies. Br J Psychiatry 2013; 202: 329-335
8. Singh I, Rose N. Biomarkers in psychiatry. Nature 2009; 460: 202-207
9. Alexopoulos GS, Meyers BS, Young RC, Campbell S, Silbersweig D, Charlson M, et al. Vascular depression hypothesis. Arch Gen Psychiatry. 1997; 54: 915-922
10. Culang-Reinlieb ME, Johnert LC, Brickman AM, Steffens DC, Garcon E, Sneed JR, et al. MRI-defined vascular depression: a review of the construct. Int J Geriatr Psychiatry 2011; 26: 1101-1108
11. Kohler S, Thomas AJ, Lloyd A, Barber R, Almeida OP, OBrien JT., et al. White matter hyperintensities, cortisol levels, brain atrophy and continuing cognitive deficits in late-life depression. BJP 2010; 196: 143-149
12. Dotson VM, Davatzikos C, Kraut MA, Resnick SM. Depressive symptoms and brain volumes in older adults: a longitudinal magnetic resonance imaging study. J Psychiatry Neurosci 2009; 34: 367-375
13. Egger K, Schocke M, Weiss E, Auffinger S, Esterhammer R, Goebel G, et al. Pattern of brain atrophy in elderly patients with depression revealed by voxel-based morphometry. Psychiatry Res 2008; 164: 237-244
14. Butters MA, Klunk WE, Mathis CA, Price JC, Ziolko SK, Hoge JA, et al. Imaging Alzheimers pathology in late-life depression with PET and Pittsburgh Compound-B. Alzheimer Dis Assoc Disord 2008; 22: 261-268
15. Kumar A, Kepe V, Barrio JR, Siddarth P, Manoukian V, Elderkin-Thompson V, et al. Protein binding in patients with late-life depression. Arch Gen Psychiatry 2011; 68: 1143-1150
16. Alexopoulos GS, Morimoto SS. The inflammation hypothesis in geriatric depression. Int J Geriatr Psychiatry 2011; 26: 1109-1118
17. Diniz BS, Teixeira AL, Campos AC, Miranda AS, Rocha NP, Talib LL, et al. Reduced serum levels of adiponectin in elderly patients with major depression. J Psychiatr Res 2012; 46: 1081-1085
18. Teixeira AL, Barbosa IG, Diniz BS, Kummer A. Circulating levels of brain-derived neurotrophic factor: correlation with mood, cognition and motor function. Biomark Med 2010; 4: 871-887
19. Diniz BS, Reynolds CF 3rd, Begley A, Dew MA, Anderson SJ, Lotrich F, et al. Brainderived neurotrophic factor levels in late-life depression and comorbid mild cognitive impairment: a longitudinal study. J Psychiatr Res 2014; 49: 96-101
20. Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, et al. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. Am J Psychiatry 2012; 169: 523-530
21. Diniz BS, Talib LL, Joaquim HP, de Paula VR, Gattaz WF, Forlenza OV, et al. Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment? World J Biol Psychiatry 2011; 12: 216-222
22. Xiao Z, Prieto D, Conrads TP, Veenstra TD, Issaq HJ. Proteomic patterns: their potential for disease diagnosis. Mol Cell Endocrinol 2005; 230: 95-106
23. Templin MF, Stoll D, Bachmann J, Joos TO. Protein microarrays and multiplexed sandwich immunoassays: what beats the beads? Comb Chem High Throughput Screen 2004; 7: 223-229
24. Arnold SE, Xie SX, Leung YY, Wang LS, Kling MA, Han X, et al. Plasma biomarkers of depressive symptoms in older adults. Transl Psychiatry 2012; 2: e65
25. Ray S, Britschgi M, Herbert C, Takeda-Uchimura Y, Boxer A, Blennow K, et al. Classification and prediction of clinical Alzheimers diagnosis based on plasma signaling proteins. Nat Med 2007; 13: 1359-1362
26. Hu WT, Chen-Plotkin A, Arnold SE, Grossman M, Clark CM, Shaw LM, et al. Novel CSF biomarkers for Alzheimers disease and mild cognitive impairment. Acta Neuropathol 2010 Jun; 119: 669-678
27. Domenici E, Willé DR, Tozzi F, Prokopenko I, Miller S, McKeown A, et al. Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections. PLoS One 2010; 5: e9166
28. Schwarz E, Guest PC, Rahmoune H, Harris LW, Wang L, Leweke FM, et al. Identification of a biological signature for schizophrenia in serum. Mol Psychiatry 2012; 17: 494-502
29. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, et al. Imaging brain amyloid in Alzheimers disease with Pittsburgh Compound-B. Ann Neurol 2004; 55: 306-319
30. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Int Med 2004; 256: 183-194
31. Wu M, Rosano C, Butters M, Whyte E, Nable M, Crooks R, et al. A fully automated method for quantifying and localizing white matter hyperintensities on MR images. Psychiatry Res 2006; 148: 133-142
32. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab 2005; 25: 1528-1547
33. Cohen AD, Price JC, Weissfeld LA, James J, Rosario BL, Bi W, et al. Basal cerebral metabolism may modulate the cognitive effects of Abeta in mild cognitive impairment: an example of brain reserve. J Neurosci 2009; 29: 14770-14778
34. Cohen AD, Mowrey W, Weissfeld LA, Aizenstein HJ, McDade E, Mountz JM, et al. Classification of amyloid-positivity in controls: comparison of visual read and quantitative approaches. Neuroimage 2013; 71: 207-215
35. Meltzer CC, Cantwell MN, Greer PJ, Ben-Eliezer D, Smith G, Frank G, et al. Does cerebral blood flow decline in healthy aging? A PET study with partial-volume correction. J Nucl Med 2000; 41: 1842-1848
36. Wang X, Lin Y, Song C, Sibille E, Tseng GC. Detecting disease-Associated genes with confounding variable adjustment and the impact on genomic meta-Analysis: with application to major depressive disorder. BMC Bioinformatics 2012; 13: 52
37. Jia Li, Tseng G. An adaptively weighted statistic for detecting differential gene expression when combining multiple transcriptomic studies. Ann Appl Stat 2011; 5: 994-1019
38. Spijker S, Van Zanten JS, De Jong S, Penninx BW, van Dyck R, Zitman FG, et al. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry 2010; 68: 179-186
39. Conrad CD. Chronic stress-induced hippocampal vulnerability: the glucocorticoid vulnerability hypothesis. Rev Neurosci 2008; 19: 395-411
40. Thomas AJ, Ferrier N, Kalaria RN, Davis S, Obrien JT. Cell adhesion molecule expression in the dorsolateral prefrontal cortex and anterior cingulate cortex in major depression in the elderly. Br J Psychiatry 2002; 181: 129-134
41. Tibshirani R. A bias correction for the minimum error rate in cross-validation. Ann Appl Stat 2009; 3: 822-829
42. Varma S, Simon R. Bias in error estimation when using cross-validation for model selection. BMC Bioinformatics 2006; 7: 91
43. Jack CR Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology 2012; 263: 344-361
44. Hughes TM, Kuller LH, Lopez OL, Becker JT, Evans RW, Sutton-Tyrrell K, et al. Markers of cholesterol metabolism in the brain show stronger associations with cerebrovascular disease than Alzheimers disease. J Alzheimers Dis 2012; 30: 53-61
45. Lotze MT. Interleukin 12: cellular and molecular immunology of an important regulatory cytokine. Introduction. Ann N Y Acad Sci 1996; 795: xiii-x
46. Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 2007; 13: 4677-4685
47. Douillard-Guilloux G, Guilloux JP, Lewis DA, Sibille E. Anticipated brain molecular aging in major depression. Am J Geriatr Psychiatry 2013; 21: 450-460
48. Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes FA, Tramontina J, et al. Allostatic load in bipolar disorder: implications for pathophysiology and treatment. Neurosci Biobehav Rev 2008; 32: 675-692
49. Sibille E. Molecular aging of the brain, neuroplasticity, and vulnerability to depression and other brain-related disorders. Dialogues Clin Neurosci 2013; 15: 53-65
50. Diniz BS, Reynolds CF 3rd, Butters MA, Dew MA, Firmo JO, Lima-Costa MF, et al. The effect of gender, age, and symptom severity in late-life depression on the risk of all-cause mortality: the Bambuí Cohort Study of Aging. Depress Anxiety advance online publication, 18 December 2013; doi: 10.1002/da.22226 (e-pub ahead of print
51. Alexopoulos GS. The vascular depression hypothesis: 10 years later. Biol Psychiatry. 2006; 60: 1304-1305
52. Sexton CE, Mackay CE, Ebmeier KP. A systematic review and meta-Analysis of magnetic resonance imaging studies in late-life depression. Am J Geriatr Psychiatry 2013; 21: 184-195
53. Andreescu C, Butters MA, Begley A, Rajji T, Wu M, Meltzer CC, et al. Gray matter changes in late life depression-A structural MRI analysis. Neuropsychopharmacology 2008; 33: 2566-2572 (e-pub ahead of print
54. Tsopelas C, Stewart R, Savva GM, Brayne C, Ince P, Thomas A, et al. Neuropathological correlates of late-life depression in older people. Br J Psychiatry. 2011; 198: 109-114
55. Koivunen J, Scheinin N, Virta JR, Aalto S, Vahlberg T, Någren K, et al. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study. Neurology 2011; 76: 1085-1090